CVS Health Corporation (CVS) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup favors a beat — CVS has averaged a 16.8% EPS surprise over the last four quarters, consensus is a modest bar, and peer read-throughs from UNH, ELV, and CNC all point to a better-than-feared Medicare Advantage utilization environment in Q2; the single biggest swing factor is whether the Medical Benefit Ratio (MBR) comes in at or below the 89.2% consensus estimate.

Heading into Q2 2026, CVS carries significant momentum: the company beat adjusted EPS by ~17% in Q1 and raised full-year guidance to $7.30–$7.50, yet consensus for Q2 sits at just $1.87 — a modest 3.3% YoY increase that implies the Street is not fully pricing in continued Aetna outperformance. Management guided to a roughly 60/40 first-half/second-half earnings split, which arithmetically implies Q2 adjusted EPS in the $1.80–$1.90 range, consistent with consensus but leaving room for upside if the MBR tracks below the full-year 90.5% ±50 bps guidance. Tone from the Q1 call was constructively cautious — management explicitly refused to flow through Q1's favorable prior-year development into the full-year outlook, preserving a conservative reserve posture that historically has been a source of positive surprises. Estimate revisions have been modestly positive since Q1 earnings (Q2 EPS consensus moved from $1.83 to $1.87), and the stock has already rallied ~20% since the Q1 print, trading near $104, suggesting some beat is priced in but not a blowout. The key wildcard is Medicaid acuity and rate alignment: peers CNC and UNH both flagged elevated Medicaid trend and membership attrition from OB3/eligibility dynamics, which could pressure Aetna's Medicaid book — though CVS's Medicaid exposure is a mid-teens share of Aetna revenue and management described Q1 Medicaid performance as strong with rates beginning to align with acuity.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a low-to-moderate bar heading into Q2 — the Street is modeling $1.87 adjusted EPS and an 89.2% MBR, both achievable given Q1's outperformance trajectory; the MBR is the bigger swing factor, as even a 50 bps beat on that metric would meaningfully exceed expectations given Aetna's Q1 84.6% print.

Table 1 — Q2 2026 Current Quarter Snapshot (All Key KPIs)

Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of August 4, 2026. HCB = Health Care Benefits segment. Adj. OI = Adjusted Operating Income.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs: Adjusted EPS & MBR)

Source: Visible Alpha Consensus and Actuals Data. Pattern: CVS has beaten adjusted EPS in 7 of the last 8 quarters with an average beat of ~15%; the lone miss (Q3 2024) was the nadir of the Aetna MA crisis. MBR beats have been more mixed, but the last three quarters show consistent improvement vs. consensus as management's conservative reserving posture has repeatedly yielded favorable development.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance was materially raised at Q1 2026 earnings (May 6) — adjusted EPS lifted by $0.30 to $7.30–$7.50 and CFO guidance raised to at least $9.5B — and no subsequent post-earnings revisions have been issued; tone remains constructively cautious with management explicitly holding a conservative MBR reserve posture until trend durability is confirmed.

Source: CVS Q1 2026 Earnings Call Transcript (May 6, 2026); Visible Alpha Consensus and Actuals Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have moved up modestly since Q1 earnings across all key metrics, tracking in line with or slightly above the raised guidance — the gap between consensus and guidance midpoints is narrow, suggesting the Street has largely digested the Q1 raise without building in additional cushion; no meaningful divergence risk is visible in the revision trail.

Source: Visible Alpha Consensus and Actuals Data; CVS Q1 2026 Earnings Call Transcript (May 6, 2026). Estimates have been remarkably stable since the Q1 raise, with Q2 EPS moving up just $0.04 and FY EPS up $0.02 — the Street has absorbed the guidance raise without adding incremental cushion, leaving room for upside if Aetna's MBR continues to track below the conservative 90.5% FY midpoint.

5. Stock Performance

Key Takeaway: CVS has rallied +20.2% since Q1 earnings (May 6, 2026), dramatically outperforming XLV (+11.5%) and the S&P 500 (+5.1%), driven by multiple re-rating as Aetna's margin recovery narrative gained credibility — the stock moved from ~$87 to ~$104, though the pace of outperformance has moderated since mid-July, suggesting the easy re-rating may be largely complete heading into Q2.

CVS vs. XLV (Health Care Select Sector SPDR) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings Date (May 6, 2026). Source: Yahoo Finance / Stock Price Data.

CVS opened at $86.86 on May 6 (Q1 earnings day) and closed at $104.42 on August 4, 2026 — a gain of +20.2% vs. XLV's +11.5% and SPY's +5.1%. The outperformance was front-loaded: CVS surged from $87 to $98 in the first week post-earnings as the Q1 beat and guidance raise were digested, then continued grinding higher through June and July as peer read-throughs (UNH, ELV) confirmed a better-than-feared MA utilization environment. The stock briefly touched $110.60 on July 21 before pulling back modestly to ~$104, suggesting some profit-taking ahead of the Q2 print. At current levels, CVS trades at roughly 13.5x the FY 2026 consensus adjusted EPS of $7.47 — still a meaningful discount to managed care peers (UNH ~18x, ELV ~15x) but the gap has narrowed materially from the trough. The sector ETF (XLV) also outperformed SPY over the period, reflecting broad managed care recovery, but CVS's alpha was company-specific and driven by the Aetna margin recovery story.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the broad confirmation from managed care peers that Medicare Advantage utilization is tracking better than feared in Q2 2026, directly de-risking CVS's Aetna MBR outlook; secondary to that, the STELARA biosimilar exclusion (July 1) and ongoing PBM transparency momentum are incremental positives for Caremark.

• [May 6, 2026] Q1 2026 Earnings Beat & Guidance Raise: CVS reported Q1 adjusted EPS of $2.57 vs. $2.19 consensus (+17.3% beat) and raised FY 2026 adjusted EPS guidance to $7.30–$7.50 from $7.00–$7.20. MBR of 84.6% was dramatically better than the 86.2% consensus. Management raised CFO guidance to at least $9.5B. Implication: Sets a high bar for Q2 but also demonstrates management's conservative reserve posture, which has historically been a source of positive surprises.
• [July 1, 2026] STELARA Biosimilar Exclusion Effective: CVS Caremark excluded branded STELARA from commercial template formularies, replacing it with lower-cost biosimilars. Management expected similar conversion rates and majority of customers to pay $0 out-of-pocket. Implication: Positive for Caremark's affordability narrative and client retention; demonstrates TrueCost model's ability to drive biosimilar adoption at scale.
• [July 16, 2026] UnitedHealth Group Q2 2026 Results: UNH reported Q2 MCR of 86.7% (including $860M favorable prior-period development) and raised FY guidance to $19.50–$20.00 adjusted EPS. Medicare cost trends running below initial ~10% estimate. Implication: Strong positive read-through for CVS Aetna — if the largest MA insurer is seeing below-plan Medicare trends, Aetna's Q2 MBR likely benefits from the same environment.
• [July 15, 2026] Elevance Health (ELV) Q2 2026 Results: ELV raised FY 2026 adjusted EPS guidance to at least $27 and reported MA results stronger than expected. Medicaid July 1 rate activity described as constructive and modestly favorable. Implication: Positive read-through for Aetna's MA and Medicaid books; ELV's Medicaid trough-year narrative (2026 = trough) is consistent with CVS's own messaging.
• [July 28–30, 2026] CNC & CI Q2 2026 Results: Centene raised FY EPS guidance to >$4.80 from >$3.40 on Marketplace and PDP outperformance; Cigna raised FY EPS to at least $30.45 on faster-than-expected biosimilar adoption and specialty strength. Implication: Biosimilar tailwind (Cigna) is a positive read-through for Caremark's specialty pharmacy economics; CNC's Medicaid rate improvement (composite rate now ~5% vs. prior 4.5%) is constructive for Aetna's Medicaid book.
• [July 29, 2026] Humana Q2 2026 Results: HUM reported cost trends in line with 7–8% all-in assumption, with slight inpatient favorability concentrated in value-based care members. On track to double individual MA pretax margin in 2026. Implication: Confirms the MA utilization environment is stabilizing; value-based care (Oak Street Health) is a differentiator for CVS in managing MA costs.
• [May 18, 2026] Annual Shareholder Meeting: Shareholders approved new compensation plan and elected directors. No material business updates disclosed. Implication: Routine governance event; no incremental signal for Q2 outlook.
• [Ongoing] PBM Transparency / CAA 2026 Transition: Industry-wide shift toward transparent, fee-based PBM models accelerating. UNH's Optum Rx committed to 100% rebate pass-through by end of 2027 (>95% of clients by year-end 2026); Cigna's 'Signature' model targeting 2028 launch. CVS's TrueCost model is already live and management views federal CAA requirements as accelerating client adoption. Implication: CVS's early-mover advantage in transparent pricing (TrueCost launched 2+ years ago) is a competitive differentiator; near-term Caremark OI pressure from client price improvements is expected and already in consensus.

7. Peer Commentaries — Q2 2026 Read-Throughs

Key Takeaway: Across all five peers reporting Q2 2026 results before CVS, the dominant theme is better-than-feared Medicare Advantage utilization with favorable prior-period development, accelerating biosimilar adoption benefiting PBM/specialty economics, and Medicaid rates beginning to catch up to trend — all three are direct positives for CVS's Aetna, Caremark, and Pharmacy segments respectively.

UnitedHealth Group (UNH) — Q2 2026 Earnings (Reported July 16, 2026)

CVS Read-Through: Strongly positive for Aetna's MBR and Caremark's PBM positioning.

• Medicare cost trends running below initial ~10% estimate: UNH stated Medicare medical cost trends are "still running well above historical levels, but below our expectations so far in 2026," driven by benefit design, care management, and network curation. UNH now expects 2026 Medicare trend to come in below the initial ~10% estimate. Read-through: If the largest MA insurer is seeing below-plan Medicare trends, Aetna's Q2 MBR likely benefits from the same macro environment, supporting CVS's conservative 90.5% FY MBR guidance as a floor rather than a ceiling.
• Favorable prior-period development: UNH's Q2 MCR of 86.7% included $860M of net favorable prior-period development (majority in-year). Days claims payable rose 2.5 days YoY to 47 days. Read-through: Industry-wide favorable development pattern is consistent with CVS's Q1 experience and suggests Q2 could again benefit from reserve releases.
• Commercial costs stubbornly high: UNH flagged commercial medical cost trends "modestly above 11%," driven by No Surprises Act IDR pressure (+100 bps total cost impact) and provider coding intensity. Read-through: CVS's commercial book is smaller relative to MA, but elevated commercial trend is a watch item for Aetna's commercial segment.
• Optum Rx PBM transparency momentum: Optum Rx committed to 100% rebate pass-through by end of 2027, with >95% of clients on 100% pass-through by year-end 2026. New pharmacy care approach announced in May based on monthly per-member fees with full PBM/GPO fee transparency. Read-through: Validates CVS's TrueCost early-mover strategy; competitive pressure on Caremark is real but CVS's 2+ year head start is a differentiator.
• MA membership retention better than anticipated: UNH now expects full-year MA enrollment to decline ~1.1M (vs. prior larger decline expectation), with MA margins finishing 2026 above 3%. Read-through: Positive for industry MA profitability trajectory; CVS guided to flat MA membership and is targeting 2028 target margins.

Elevance Health (ELV) — Q2 2026 Earnings (Reported July 15, 2026)

CVS Read-Through: Positive for Aetna's MA and Medicaid segments; confirms 2026 as the trough year for managed care margins.

• MA results stronger than expected: ELV's deliberate portfolio actions for 2026 (disciplined plan design, focused product mix) translated into improved MA performance, supporting a path to at least 2% MA operating margin for 2026. Read-through: Consistent with CVS Aetna's disciplined 2026 MA strategy; both companies took similar benefit design actions and are seeing similar improvement.
• Medicaid July 1 rates constructive: ELV described July 1 Medicaid rate activity as "constructive and modestly favorable to expectations," with mid-single digit percent rate updates potentially toward the upper end. Read-through: Positive for Aetna's Medicaid book; CVS management described Q1 Medicaid as strong with rates beginning to align with acuity, and ELV's July 1 data point suggests this trend continued into Q2/Q3.
• 2026 as Medicaid trough: ELV continues to view 2026 as the trough year for Medicaid margin, with improvement expected over time supported by better rate alignment and maturing care management. Full-year Medicaid operating margin outlook ~-1.75%. Read-through: Consistent with CVS's messaging; Medicaid headwinds are known and priced in.
• Cost drivers concentrated in behavioral health, specialty pharmacy, outpatient surgery, ED: ELV flagged these as the primary elevated cost categories, with actions being taken through clinical oversight and payment integrity. Read-through: Same cost drivers CVS has flagged; no new surprises in the cost environment.
• FY 2026 guidance raised to at least $27 adjusted EPS: ELV raised guidance and now views at least $26 as the appropriate 2027 earnings baseline, expressing confidence in returning to at least 12% adjusted EPS growth in 2027. Read-through: Sector-wide earnings recovery narrative gaining credibility, which supports CVS's mid-teens EPS CAGR through 2028 commitment.

Humana (HUM) — Q2 2026 Earnings (Reported July 29, 2026)

CVS Read-Through: Positive for Aetna's MA margin recovery trajectory; value-based care (Oak Street) differentiation confirmed.

• Cost trends in line with 7–8% all-in assumption: HUM's all-in trend (medical + pharmacy) tracking to 7–8%, with slight inpatient favorability concentrated in value-based care members (lower admits per 1,000 and lower unit costs). Read-through: Confirms the MA utilization environment is not deteriorating further; value-based care's ability to reduce inpatient costs is a direct positive for CVS's Oak Street Health strategy.
• On track to double individual MA pretax margin in 2026: HUM remains on track to meet Investor Day commitments, including doubling individual MA pretax margin this year (excluding Stars headwind), with operating cost ratio down ~150 bps YoY. Read-through: Industry-wide MA margin recovery is real and progressing; CVS's Aetna is on a similar trajectory toward 2028 target margins.
• 2027 plan exits impacting ~600K members: HUM plans to exit plans affecting ~600K members in 2027, prioritizing higher-performing plans with greater value-based care penetration. Read-through: Industry rationalization of MA footprint is ongoing; CVS's flat MA membership guidance reflects similar discipline.
• Drug costs in double digits: HUM's drug cost trend is in the double digits and expected to tick modestly higher in 2027 due to the health technology pipeline. Read-through: Elevated specialty drug trend is a persistent headwind for all managed care; CVS's Caremark/TrueCost model is positioned to help clients manage this.
• Illinois Medicaid contract awarded: HUM was awarded a statewide Illinois Medicaid managed care contract (go-live January 2027), the only new entrant alongside five incumbents. Read-through: Neutral for CVS; confirms Medicaid managed care market remains competitive.

Centene Corporation (CNC) — Q2 2026 Earnings (Reported July 28, 2026)

CVS Read-Through: Mixed — positive on Medicaid rate improvement and MA profitability; watch item on Medicaid membership attrition from OB3/eligibility dynamics.

• Consolidated HBR improved to 89.6% in Q2 (from 93% in Q2 2025): CNC's Q2 HBR of 89.6% was a significant improvement, driven by Marketplace outperformance (79.2% HBR vs. 90.6% prior year) and Medicare outperformance. Read-through: Broad-based MBR improvement across the industry is a positive signal for Aetna's Q2 MBR.
• Medicaid composite rate forecast improved to ~5% (from ~4.5%): July 1 Medicaid rates came in better than expected, improving CNC's full-year composite rate forecast. Read-through: Positive for Aetna's Medicaid book; rate alignment with acuity is progressing across the industry.
• Medicaid membership attrition from OB3/eligibility activity: CNC expects full-year Medicaid membership down 8–9% vs. December 31, 2025 (worse than prior -6% view), driven by state-specific program changes and increased enrollment/eligibility activity. Expansion population attrition expected to continue through 2027–2029. Read-through: Watch item for Aetna's Medicaid membership; CVS's Medicaid exposure is mid-teens of Aetna revenue, so attrition is manageable but worth monitoring.
• MA getting closer to breakeven for full year 2026: CNC's MA business (>40% of Medicare segment revenue) is approaching breakeven for 2026, with D-SNP members (~40% of MA portfolio) performing favorably. Read-through: Consistent with industry-wide MA margin recovery; CVS's Aetna is on a similar path.
• Specialty drug trends elevated but below original expectations: CNC noted specialty drug trends remain elevated but lower than original H1 expectations, with PDP now expected to deliver >3% pretax margin (vs. initial 2% guidance). Read-through: Positive for CVS's Caremark PBM and pharmacy segments; specialty drug trend moderation is a tailwind.

Cigna Group (CI) — Q2 2026 Earnings (Reported July 30, 2026)

CVS Read-Through: Positive for Caremark's specialty pharmacy and biosimilar economics; GLP-1 moderation is a nuanced read-through.

• Faster-than-expected biosimilar and specialty generic adoption: CI saw specialty generic penetration exceed 80% for newer products in Q2, with biosimilar/specialty generic adoption contributing favorably to earnings. Evernorth specialty and care services delivered 22% YoY pre-tax earnings growth. Read-through: Strong positive for CVS Caremark's specialty pharmacy economics; biosimilar adoption (including the July 1 STELARA exclusion) is a direct earnings tailwind for Caremark.
• GLP-1 growth moderating: CI observed moderating GLP-1 growth in Q2, with coverage levels slightly declining and utilization growth slowing from prior elevated levels. Only 15–20% of CI's employer book covers GLP-1 for weight management. CI ended its own employee GLP-1 weight management coverage on July 1. Read-through: Nuanced for CVS — GLP-1 moderation reduces a revenue tailwind for Caremark's pharmacy volume, but CVS's CostVantage model has "neutralized" the margin impact (not losing money, not overearning). CVS noted a 200 bps improvement in GLP-1 script share.
• PBM 'Signature' model gaining traction: CI's rebate-free 'Signature' model is seeing significant early interest ahead of its 2028 broader market launch; 2027 selling season is the strongest in recent years with new business above the prior two seasons combined. Retention at >97% for 2026. Read-through: Competitive pressure on Caremark is real, but CVS's TrueCost model is already live and has maintained >98% client retention with strong net new wins for the 2026 selling season.
• Medical cost trends elevated but stable: CI's Q2 MCR of 84.5% was slightly ahead of expectations, with high single-digit cost trends persisting. Lower outpatient trends (including reduced surgical spend) drove modest favorability. Read-through: Consistent with the broader industry picture; no new cost acceleration signals.
• Specialty pharmacy TAM approaching $500B: CI highlighted the specialty pharmacy market approaching a $500B TAM with high single-digit secular growth, with 60% direct-to-patient (Accredo) and 40% provider-administered. Read-through: Validates CVS's specialty pharmacy strategy through Caremark/Accredo; secular growth in specialty is a multi-year tailwind for the entire PBM/specialty pharmacy industry.

Summary Read-Through Table

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells from senior executives since Q1 earnings — the only notable transaction is a $1.98M open-market sale by Director Larry Robbins (Glenview Capital) on May 19, which is likely portfolio management by the activist fund rather than a negative signal; all other transactions are routine tax-withholding forfeitures (code F) or annual director equity grants (code A), which carry no informational content.

Source: Insider Transaction Data (SEC Form 4 filings, May 6 – August 4, 2026). Open-market buy/sell codes: P = open-market purchase, S = open-market sale, F = tax withholding forfeiture (not discretionary), A = award/grant, D = disposition (non-market). No open-market purchases (code P) were filed by any CVS insider during the period. The absence of insider buying is not unusual given the stock's +20% post-earnings rally; the Robbins sale is the only transaction of note and is likely Glenview portfolio management rather than a negative fundamental signal.

— End of CVS Health Q2 2026 Earnings Preview —